Cardiac Arrhythmia Service, Icahn School of Medicine at Mount Sinai, New York, New York.
Cardiac Arrhythmia Service, Icahn School of Medicine at Mount Sinai, New York, New York.
J Am Coll Cardiol. 2017 May 2;69(17):2119-2129. doi: 10.1016/j.jacc.2017.02.059.
A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization therapy (CRT) either do not respond to conventional CRT or remain untreated due to an inability or impediment to coronary sinus (CS) lead implantation. The WiSE-CRT system (EBR Systems, Sunnyvale, California) was developed to address this at-risk patient population by performing biventricular pacing via a wireless left ventricular (LV) endocardial pacing electrode.
The SELECT-LV (Safety and Performance of Electrodes implanted in the Left Ventricle) study is a prospective multicenter non-randomized trial assessing the safety and performance of the WiSE-CRT system.
A total of 35 patients indicated for CRT who had "failed" conventional CRT underwent implantation of an LV endocardial pacing electrode and a subcutaneous pulse generator. System performance, clinical efficacy, and safety events were assessed out to 6 months post-implant.
The procedure was successful in 97.1% (n = 34) of attempted implants. The most common indications for endocardial LV pacing were difficult CS anatomy (n =12), failure to respond to conventional CRT (n = 10), and a high CS pacing threshold or phrenic nerve capture (n = 5). The primary performance endpoint, biventricular pacing on the 12-lead electrocardiogram at 1 month, was achieved in 33 of 34 patients. A total of 28 patients (84.8%) had improvement in the clinical composite score at 6 months, and 21 (66%) demonstrated a positive echocardiographic CRT response (≥5% absolute increase in LV ejection fraction). There were no pericardial effusions, but serious procedure/device-related events occurred in 3 patients (8.6%) within 24 h, and 8 patients (22.9%) between 24 h and 1 month.
The SELECT-LV study demonstrates the clinical feasibility for the WiSE-CRT system, and provided clinical benefits to a majority of patients within an otherwise "failed" CRT population. (Safety and Performance of Electrodes Implanted in the Left Ventricle [SELECT-LV]; NCT01905670).
充血性心力衰竭患者中有 30%到 40%适合接受心脏再同步治疗(CRT),但由于无法或难以植入冠状窦(CS)导联,要么对常规 CRT 无反应,要么未得到治疗。WiSE-CRT 系统(EBR Systems,加利福尼亚州森尼韦尔)的开发是为了解决这一高危患者群体的问题,通过无线左心室(LV)心内膜起搏电极实现双心室起搏。
SELECT-LV(左心室植入电极的安全性和性能)研究是一项前瞻性多中心非随机试验,评估 WiSE-CRT 系统的安全性和性能。
共有 35 名符合 CRT 适应证且“失败”常规 CRT 的患者接受了 LV 心内膜起搏电极和皮下脉冲发生器的植入。在植入后 6 个月内评估系统性能、临床疗效和安全性事件。
尝试植入的 35 例患者中,手术成功率为 97.1%(n=34)。心内膜 LV 起搏最常见的适应证是 CS 解剖困难(n=12)、对常规 CRT 无反应(n=10)和 CS 起搏阈值高或膈神经捕获(n=5)。主要性能终点,即 1 个月时 12 导联心电图上的双心室起搏,在 34 例患者中有 33 例达到。共有 28 例(84.8%)患者在 6 个月时临床综合评分得到改善,21 例(66%)表现出超声心动图 CRT 反应阳性(LV 射血分数绝对值增加≥5%)。无心包积液,但 3 例(8.6%)患者在 24 小时内发生严重的手术/器械相关事件,8 例(22.9%)患者在 24 小时至 1 个月内发生严重的手术/器械相关事件。
SELECT-LV 研究证明了 WiSE-CRT 系统的临床可行性,并为大多数否则“失败”的 CRT 人群提供了临床益处。(左心室植入电极的安全性和性能[SELECT-LV];NCT01905670)。